Ashton Thomas Private Wealth LLC Takes $282,000 Position in InMode Ltd. (NASDAQ:INMD)

Ashton Thomas Private Wealth LLC bought a new stake in shares of InMode Ltd. (NASDAQ:INMD) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 16,896 shares of the healthcare company’s stock, valued at approximately $282,000.

Several other hedge funds have also recently made changes to their positions in the business. Raymond James Financial Inc. purchased a new stake in shares of InMode during the 4th quarter valued at about $1,332,000. Seizert Capital Partners LLC raised its position in shares of InMode by 105.2% during the 4th quarter. Seizert Capital Partners LLC now owns 250,627 shares of the healthcare company’s stock valued at $4,185,000 after buying an additional 128,483 shares in the last quarter. Atria Investments Inc raised its position in InMode by 23.1% in the 4th quarter. Atria Investments Inc now owns 15,088 shares of the healthcare company’s stock worth $252,000 after purchasing an additional 2,828 shares during the period. Marathon Asset Management Ltd raised its position in InMode by 57.4% in the 4th quarter. Marathon Asset Management Ltd now owns 182,349 shares of the healthcare company’s stock worth $3,045,000 after purchasing an additional 66,475 shares during the period. Finally, SBI Securities Co. Ltd. purchased a new stake in InMode in the 4th quarter worth about $87,000. 68.04% of the stock is currently owned by hedge funds and other institutional investors.

InMode Price Performance

Shares of INMD stock opened at $18.81 on Wednesday. The company has a market capitalization of $1.31 billion, a P/E ratio of 8.00 and a beta of 2.07. The company’s 50-day simple moving average is $17.84 and its two-hundred day simple moving average is $17.57. InMode Ltd. has a one year low of $14.87 and a one year high of $22.00.

Analysts Set New Price Targets

INMD has been the topic of a number of recent analyst reports. Needham & Company LLC reissued a “hold” rating on shares of InMode in a research report on Tuesday, February 4th. Barclays increased their price objective on shares of InMode from $26.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 5th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $22.25.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.